Background/aim Prader-Willi syndrome (PWS) and Angelman syndrome (AS) are rare imprinting disorders caused by the aberrant ...

Ionis Pharmaceuticals has dosed the first subject in the global, randomised Phase III REVEAL trial of investigational ION582.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the first participant has been dosed in the global Phase 3 ...

Ivor Washbrook loves climbing trees and singing and dancing with his sisters. He also has a syndrome that will affect his ...

Stetson was diagnosed with Angelman syndrome a couple months later, when the results of genetic blood work revealed that he had a deleted gene on the maternally derived Chromosome 15. The neurogenetic ...

It also causes seizures. Money raised will help support an Angelman Syndrome clinic at Cincinnati Children's Hospital.

We performed a single-arm open-label trial in which 25 children diagnosed with Angelman syndrome (AS) were administered minocycline to assess the safety and tolerability of minocycline in this ...

A mum in Monmouth describes her fears about managing her severely disabled son's care needs.

A child with Angelman syndrome – which affects around one in 21,000 births worldwide – will typically begin to show signs of delayed development at around six to 12 months. There are no ...

The firm expects to complete enrolling the REVEAL trial, in which patients will receive the ASO, dubbed ION582, in 2026.